Emese Vágó
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Emese Vágó has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Erzsébet Horváth-Puhó
Department of Clinical Epidemiology, Center for Population Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
2 shared publications - Frida Schain
Schain Research AB Bromma Sweden
2 shared publications - Henrik Toft Sørensen
Department of Clinical Epidemiology Center for Population Medicine, Aarhus University and Aarhus University Hospital Aarhus Denmark
2 shared publications Sándor Kemény
Department of Chemical and Environmental Process Engineering Budapest University of Technology and Economics Műegyetem rkp. 3. Budapest H‐1111 Hungary
2 shared publications- Sándor Kemény
Department of Chemical and Environmental Process Engineering Budapest University of Technology and Economics Budapest Hungary
2 shared publications A. Balogh
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 18, 1-12
Cohort Profile: The Central Denmark Cancer Cohort
Purpose: Cancer outcome studies frequently utilize registry data, which provide large-scale population-level information. However, these registries often lack detailed clinical information regarding comorbidities, lifestyle factors, and in-hospital treatments. The Central Denmark Cancer Cohort (CDCC) was established to address these limitations by linking medical and administrative registry data with clinical electronic medical records (EMR), to facilitate research to better understand the clinical course of cancer and its complications. Patients and Methods: The CDCC includes all patients with incident cancer, except non-melanoma skin cancer, diagnosed in the Central Denmark Region between 2012 and 2021, with complete follow-up through December 31, 2021. The CDCC was identified from the Danish Cancer Registry and linked via the Civil Personal Registration number to the Central Denmark Region Clinical Information System (CDRCIS) and to national registries, including the Danish National Patient Registry, National Prescription Registry, and Register of Laboratory Results for Research. We extracted data on demographics, lifestyle factors, comorbidities, treatments, and survival outcomes and assessed the availability of these data. Results: The CDCC included 68,028 patients with a median age of 68 years (interquartile range: 59– 76 years); 47.2% were female. The most common cancers were prostate cancer (10,024 patients), breast cancer (9,100 patients), and non-small cell lung carcinoma (7,264 patients). At diagnosis, 98.0% of patients had laboratory test results available, 87.5% received at least one in-hospital medication, and 86.9% had at least one characteristic documented in CDRCIS. During median follow-up of 2.6 years, 37.8% of patients died and five-year survival was 59.0% (95% confidence interval: 58.6– 59.4%). Data completeness varied by cancer type. Conclusion: The CDCC integrates clinical, lifestyle, and laboratory data with cancer registry information. By capturing factors typically unavailable in registry-based research, this platform offers a unique foundation for longitudinal studies on the clinical course of cancer.
- 1 June 2026
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 18, 1-12
Open AccessCohort Profile: The Central Denmark Cancer Cohort
Purpose: Cancer outcome studies frequently utilize registry data, which provide large-scale population-level information. However, these registries often lack detailed clinical information regarding comorbidities, lifestyle factors, and in-hospital treatments. The Central Denmark Cancer Cohort (CDCC) was established to address these limitations by linking medical and administrative registry data with clinical electronic medical records (EMR), to facilitate research to better understand the clinical course of cancer and its complications. Patients and Methods: The CDCC includes all patients with incident cancer, except non-melanoma skin cancer, diagnosed in the Central Denmark Region between 2012 and 2021, with complete follow-up through December 31, 2021. The CDCC was identified from the Danish Cancer Registry and linked via the Civil Personal Registration number to the Central Denmark Region Clinical Information System (CDRCIS) and to national registries, including the Danish National Patient Registry, National Prescription Registry, and Register of Laboratory Results for Research. We extracted data on demographics, lifestyle factors, comorbidities, treatments, and survival outcomes and assessed the availability of these data. Results: The CDCC included 68,028 patients with a median age of 68 years (interquartile range: 59– 76 years); 47.2% were female. The most common cancers were prostate cancer (10,024 patients), breast cancer (9,100 patients), and non-small cell lung carcinoma (7,264 patients). At diagnosis, 98.0% of patients had laboratory test results available, 87.5% received at least one in-hospital medication, and 86.9% had at least one characteristic documented in CDRCIS. During median follow-up of 2.6 years, 37.8% of patients died and five-year survival was 59.0% (95% confidence interval: 58.6– 59.4%). Data completeness varied by cancer type. Conclusion: The CDCC integrates clinical, lifestyle, and laboratory data with cancer registry information. By capturing factors typically unavailable in registry-based research, this platform offers a unique foundation for longitudinal studies on the clinical course of cancer.
- Open Access
- 22 December 2022
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 9 (1) , e001281
Registry-based cohort study of alpha-1 antitrypsin deficiency prevalence, incidence and mortality in Denmark 2000–2018
Objective To estimate the prevalence of diagnosed alpha-1 antitrypsin deficiency (dAATD) in Denmark as of 31 December 2018, and dAATD incidence and mortality from 1 January 2000 to 31 December 2018. Study design and setting We used the Danish National Patient Registry to identify patients with dAATD based on the International Classification of Diseases, 10th Revision (ICD-10) code E88.0A and the Danish Civil Registration System (CRS) for population counts and vital status. We estimated dAATD prevalence, incidence and mortality. We compared mortality among patients with dAATD and an age-matched and sex-matched cohort extracted from the Danish CRS. We conducted a sensitivity analysis to examine whether coding changes during 2000–2018, from a general to a more specific ICD-10 code for AATD, and left truncation affected results appreciably. Results The prevalence of dAATD was 12.9 (95% CI 11.9 to 13.8) per 100 000 persons. The age distribution was bimodal, with peaks at ages ≤12 and ≥45 years. The incidence rate per 100 000 person-years was 0.90 (95% CI 0.85 to 0.96), again with a bimodal age distribution. Mortality was higher for patients with dAATD than for the general population (mortality rate ratio (mRR) 4.7, 95% CI 4.1 to 5.3), especially for children (mRR 33.8, 95% CI 6.8 to 167.4). The sensitivity analysis indicated that dAATD prevalence might have been as high as 19.7 per 100 000 persons due to less specific ICD-10 coding for AATD early in the study period or 21.4 per 100 000 persons correcting for left truncation. Conclusion Diagnosed AATD was associated with increased mortality, especially for children. The finding for children was based on few deaths and had very wide 95% CIs.
- 22 December 2022
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 9 (1) , e001281
Open AccessRegistry-based cohort study of alpha-1 antitrypsin deficiency prevalence, incidence and mortality in Denmark 2000–2018
Objective To estimate the prevalence of diagnosed alpha-1 antitrypsin deficiency (dAATD) in Denmark as of 31 December 2018, and dAATD incidence and mortality from 1 January 2000 to 31 December 2018. Study design and setting We used the Danish National Patient Registry to identify patients with dAATD based on the International Classification of Diseases, 10th Revision (ICD-10) code E88.0A and the Danish Civil Registration System (CRS) for population counts and vital status. We estimated dAATD prevalence, incidence and mortality. We compared mortality among patients with dAATD and an age-matched and sex-matched cohort extracted from the Danish CRS. We conducted a sensitivity analysis to examine whether coding changes during 2000–2018, from a general to a more specific ICD-10 code for AATD, and left truncation affected results appreciably. Results The prevalence of dAATD was 12.9 (95% CI 11.9 to 13.8) per 100 000 persons. The age distribution was bimodal, with peaks at ages ≤12 and ≥45 years. The incidence rate per 100 000 person-years was 0.90 (95% CI 0.85 to 0.96), again with a bimodal age distribution. Mortality was higher for patients with dAATD than for the general population (mortality rate ratio (mRR) 4.7, 95% CI 4.1 to 5.3), especially for children (mRR 33.8, 95% CI 6.8 to 167.4). The sensitivity analysis indicated that dAATD prevalence might have been as high as 19.7 per 100 000 persons due to less specific ICD-10 coding for AATD early in the study period or 21.4 per 100 000 persons correcting for left truncation. Conclusion Diagnosed AATD was associated with increased mortality, especially for children. The finding for children was based on few deaths and had very wide 95% CIs.
- Open Access
- 19 September 2019
- Published by Wiley in European Journal of Haematology
- Vol. 103 (6) , 614-619
Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population‐based cohort study in Sweden and Norway
Objective: To estimate survival in Swedish and Norwegian myelofibrosis (MF) patients who received ruxolitinib.Methods: Swedish and Norwegian patients with MF diagnosis in the National Cancer Registries (Sweden: 2001‐2015; Norway: 2002‐2016) and ≥1 record of ruxolitinib in the Prescribed Drug Registries (2013‐2017) were included. Patients were followed from ruxolitinib initiation until death or end of follow‐up; those who discontinued ruxolitinib were followed from ruxolitinib discontinuation. Relative survival (RS) and excess mortality rate ratios (EMRRs) were calculated vs a matched general population. Average loss in life expectancy (LEL) was predicted using flexible parametric models.Results: Among patients who initiated ruxolitinib (n = 190), 1‐ and 4‐year RS were 0.80 (95% confidence interval [CI]: 0.74, 0.86) and 0.52 (95% CI: 0.42, 0.64), respectively, and LEL was 11 years. EMRR was greater in patients aged >70 vs <60 years (3.16; 95% CI: 1.34‐7.40). Among patients who discontinued ruxolitinib (n = 71), median RS was 16.0 months (95% CI: 6.3, NE), and LEL was 12 years. After ruxolitinib treatment discontinuation, Swedish patients (n = 37) received glucocorticoids, hydroxyurea, busulfan, danazol and lenalidomide.Conclusion: Swedish and Norwegian MF patients who discontinued ruxolitinib had dismal survival outcomes and limited subsequent treatment options, highlighting the need for improved therapies.
- 19 September 2019
- Published by Wiley in European Journal of Haematology
- Vol. 103 (6) , 614-619
Open AccessSurvival outcomes in myelofibrosis patients treated with ruxolitinib: A population‐based cohort study in Sweden and Norway
Objective: To estimate survival in Swedish and Norwegian myelofibrosis (MF) patients who received ruxolitinib.Methods: Swedish and Norwegian patients with MF diagnosis in the National Cancer Registries (Sweden: 2001‐2015; Norway: 2002‐2016) and ≥1 record of ruxolitinib in the Prescribed Drug Registries (2013‐2017) were included. Patients were followed from ruxolitinib initiation until death or end of follow‐up; those who discontinued ruxolitinib were followed from ruxolitinib discontinuation. Relative survival (RS) and excess mortality rate ratios (EMRRs) were calculated vs a matched general population. Average loss in life expectancy (LEL) was predicted using flexible parametric models.Results: Among patients who initiated ruxolitinib (n = 190), 1‐ and 4‐year RS were 0.80 (95% confidence interval [CI]: 0.74, 0.86) and 0.52 (95% CI: 0.42, 0.64), respectively, and LEL was 11 years. EMRR was greater in patients aged >70 vs <60 years (3.16; 95% CI: 1.34‐7.40). Among patients who discontinued ruxolitinib (n = 71), median RS was 16.0 months (95% CI: 6.3, NE), and LEL was 12 years. After ruxolitinib treatment discontinuation, Swedish patients (n = 37) received glucocorticoids, hydroxyurea, busulfan, danazol and lenalidomide.Conclusion: Swedish and Norwegian MF patients who discontinued ruxolitinib had dismal survival outcomes and limited subsequent treatment options, highlighting the need for improved therapies.
- 20 May 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (15_suppl) , e16555
Survival in men diagnosed with castration resistant prostate cancer: A population-based observational study in Sweden.
E16555 Background: Data focusing on the castration resistant phase of prostate cancer (PC) outside clinical trial settings are scarce. This study aims to investigate PC-specific and overall survival (OS) in men with castration resistant prostate cancer (CRPC) on a population level. Methods: The STHLM-0 cohort (n = 400 000) with data on all prostate specific antigen (PSA) values and prostate biopsies taken in Stockholm, Sweden, from 2003 to 2015 were linked to other population registries. All men with a PC diagnosis and rising PSA after three months consecutive use of gonadotropin-releasing hormone or surgical castration were defined as CRPC (n = 1712). Kaplan-Meier was used to estimate median time-to-event and 95% confidence intervals (CI). Patients were stratified by metastasis status at PC diagnosis and multivariable Cox regression was used to adjust for clinical subgroups, including Gleason, age, T stage and calendar period (2006-2011 vs 2012-2015). Results: Metastasis at PC diagnosis was associated with shorter OS from castration resistance. From CRPC onset the median OS was 22.8 months (95% CI 21.2-25.5) and 13.1 (95% CI 11.5-14.2) months for patients without and with metastasis at PC diagnosis, respectively. The median PC-specific survival from CRPC was 30.7 (95% CI 27.9-34.7) months and 13.5 (95% CI 12.3-16.1) months for patients without and with metastasis at PC diagnosis, respectively. For patients with metastasis at PC diagnosis, factors influencing OS from CRPC were; entering CRPC stage in the later vs earlier calendar period (HR 0.61 95% CI 0.48-0.78, p < 0.001), age > 80 vs < 70 (HR 1.46, 95% CI 1.05-2.02, p < 0.02), T4 vs T1 stage (HR 1.56, 95% CI:1.02-2.37, p < 004). For patients without metastasis at PC diagnosis, developing CRPC in the later vs the earlier calendar period was associated with superior survival from CRPC (HR 0.78 95% CI 0.65-0.92, p < 0.004). Conclusions: Metastasis at PC diagnosis was associated with worse survival outcomes in CRPC patients. Individuals who became castration resistant in the later calendar period survived longer compared to those in the same stage in the earlier calendar period, most likely due to the introduction of novel agents for CRPC patients and more accurate staging methods.
- 20 May 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (15_suppl) , e16555
Survival in men diagnosed with castration resistant prostate cancer: A population-based observational study in Sweden.
E16555 Background: Data focusing on the castration resistant phase of prostate cancer (PC) outside clinical trial settings are scarce. This study aims to investigate PC-specific and overall survival (OS) in men with castration resistant prostate cancer (CRPC) on a population level. Methods: The STHLM-0 cohort (n = 400 000) with data on all prostate specific antigen (PSA) values and prostate biopsies taken in Stockholm, Sweden, from 2003 to 2015 were linked to other population registries. All men with a PC diagnosis and rising PSA after three months consecutive use of gonadotropin-releasing hormone or surgical castration were defined as CRPC (n = 1712). Kaplan-Meier was used to estimate median time-to-event and 95% confidence intervals (CI). Patients were stratified by metastasis status at PC diagnosis and multivariable Cox regression was used to adjust for clinical subgroups, including Gleason, age, T stage and calendar period (2006-2011 vs 2012-2015). Results: Metastasis at PC diagnosis was associated with shorter OS from castration resistance. From CRPC onset the median OS was 22.8 months (95% CI 21.2-25.5) and 13.1 (95% CI 11.5-14.2) months for patients without and with metastasis at PC diagnosis, respectively. The median PC-specific survival from CRPC was 30.7 (95% CI 27.9-34.7) months and 13.5 (95% CI 12.3-16.1) months for patients without and with metastasis at PC diagnosis, respectively. For patients with metastasis at PC diagnosis, factors influencing OS from CRPC were; entering CRPC stage in the later vs earlier calendar period (HR 0.61 95% CI 0.48-0.78, p < 0.001), age > 80 vs < 70 (HR 1.46, 95% CI 1.05-2.02, p < 0.02), T4 vs T1 stage (HR 1.56, 95% CI:1.02-2.37, p < 004). For patients without metastasis at PC diagnosis, developing CRPC in the later vs the earlier calendar period was associated with superior survival from CRPC (HR 0.78 95% CI 0.65-0.92, p < 0.004). Conclusions: Metastasis at PC diagnosis was associated with worse survival outcomes in CRPC patients. Individuals who became castration resistant in the later calendar period survived longer compared to those in the same stage in the earlier calendar period, most likely due to the introduction of novel agents for CRPC patients and more accurate staging methods.
- 8 February 2018
- Published by Wiley in Journal of Chemometrics
- Vol. 32 (4)
Decision risk approach to the application of biological indicators in vapor phased hydrogen peroxide bio‐decontamination
The ensuring of sterile conditions during pharmaceutical production is of vital importance. Restricted access barrier systems may not be sterilized in the usual way. Instead, vaporous hydrogen peroxide decontamination is used. The success of the decontamination is checked by placing biological indicators (BIs), and upon their removal, putting them individually into broth for incubation. This technique does not allow counting the number of microorganisms but to detect the survival of any of them and thus counting the negative/positive answers. The Poisson distribution gives the connection between the number of viable spores and the number of positive (growth) BIs. Evaluation is based on the number of surviving BIs, which is probabilistic by nature. Acceptance limits are based on good engineering assumptions (“current industrial experience”), not on sound decision theory statistics (probability of error of the first and second kind). The reason of existence of surviving BI is either the process lethality failure or the limited penetrative capability of vaporous hydrogen peroxide. The latter phenomenon is called “rogue” BIs, and it should be distinguished. The method of the evaluation of the success of the decontamination is consistent with attribute sampling plans. In this paper, relations are explored to calculate the 2 types of error that can be applied in general during the qualification of a bio‐decontamination procedure. This is, to the best knowledge of the authors, the first ever application of attribute sampling plans to evaluate the results of a BI used bio‐decontamination process.
- 8 February 2018
- Published by Wiley in Journal of Chemometrics
- Vol. 32 (4)
Decision risk approach to the application of biological indicators in vapor phased hydrogen peroxide bio‐decontamination
The ensuring of sterile conditions during pharmaceutical production is of vital importance. Restricted access barrier systems may not be sterilized in the usual way. Instead, vaporous hydrogen peroxide decontamination is used. The success of the decontamination is checked by placing biological indicators (BIs), and upon their removal, putting them individually into broth for incubation. This technique does not allow counting the number of microorganisms but to detect the survival of any of them and thus counting the negative/positive answers. The Poisson distribution gives the connection between the number of viable spores and the number of positive (growth) BIs. Evaluation is based on the number of surviving BIs, which is probabilistic by nature. Acceptance limits are based on good engineering assumptions (“current industrial experience”), not on sound decision theory statistics (probability of error of the first and second kind). The reason of existence of surviving BI is either the process lethality failure or the limited penetrative capability of vaporous hydrogen peroxide. The latter phenomenon is called “rogue” BIs, and it should be distinguished. The method of the evaluation of the success of the decontamination is consistent with attribute sampling plans. In this paper, relations are explored to calculate the 2 types of error that can be applied in general during the qualification of a bio‐decontamination procedure. This is, to the best knowledge of the authors, the first ever application of attribute sampling plans to evaluate the results of a BI used bio‐decontamination process.
- Open Access
- 28 December 2017
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (2) , 148-160
Methods for time‐varying exposure related problems in pharmacoepidemiology: An overview
Purpose: Lack of control for time‐varying exposures can lead to substantial bias in estimates of treatment effects. The aim of this study is to provide an overview and guidance on some of the available methodologies used to address problems related to time‐varying exposure and confounding in pharmacoepidemiology and other observational studies. The methods are explored from a conceptual rather than an analytical perspective.Methods: The methods described in this study have been identified exploring the literature concerning to the time‐varying exposure concept and basing the search on four fundamental pharmacoepidemiological problems, construction of treatment episodes, time‐varying confounders, cumulative exposure and latency, and treatment switching.Results: A correct treatment episodes construction is fundamental to avoid bias in treatment effect estimates. Several methods exist to address time‐varying covariates, but the complexity of the most advanced approaches—eg, marginal structural models or structural nested failure time models—and the lack of user‐friendly statistical packages have prevented broader adoption of these methods. Consequently, simpler methods are most commonly used, including, for example, methods without any adjustment strategy and models with time‐varying covariates. The magnitude of exposure needs to be considered and properly modelled.Conclusions: Further research on the application and implementation of the most complex methods is needed. Because different methods can lead to substantial differences in the treatment effect estimates, the application of several methods and comparison of the results is recommended. Treatment episodes estimation and exposure quantification are key parts in the estimation of treatment effects or associations of interest.
- 28 December 2017
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (2) , 148-160
Open AccessMethods for time‐varying exposure related problems in pharmacoepidemiology: An overview
Purpose: Lack of control for time‐varying exposures can lead to substantial bias in estimates of treatment effects. The aim of this study is to provide an overview and guidance on some of the available methodologies used to address problems related to time‐varying exposure and confounding in pharmacoepidemiology and other observational studies. The methods are explored from a conceptual rather than an analytical perspective.Methods: The methods described in this study have been identified exploring the literature concerning to the time‐varying exposure concept and basing the search on four fundamental pharmacoepidemiological problems, construction of treatment episodes, time‐varying confounders, cumulative exposure and latency, and treatment switching.Results: A correct treatment episodes construction is fundamental to avoid bias in treatment effect estimates. Several methods exist to address time‐varying covariates, but the complexity of the most advanced approaches—eg, marginal structural models or structural nested failure time models—and the lack of user‐friendly statistical packages have prevented broader adoption of these methods. Consequently, simpler methods are most commonly used, including, for example, methods without any adjustment strategy and models with time‐varying covariates. The magnitude of exposure needs to be considered and properly modelled.Conclusions: Further research on the application and implementation of the most complex methods is needed. Because different methods can lead to substantial differences in the treatment effect estimates, the application of several methods and comparison of the results is recommended. Treatment episodes estimation and exposure quantification are key parts in the estimation of treatment effects or associations of interest.
- 1 June 2017
- Published by Elsevier in Advanced Powder Technology
- Vol. 28 (6) , 1554-1563
Development and tableting of directly compressible powder from electrospun nanofibrous amorphous solid dispersion
- 1 June 2017
- Published by Elsevier in Advanced Powder Technology
- Vol. 28 (6) , 1554-1563
Development and tableting of directly compressible powder from electrospun nanofibrous amorphous solid dispersion
- 26 October 2011
- Published by Wiley in Quality and Reliability Engineering International
- Vol. 28 (8) , 807-823
Random Effects Model for Attribute Gauge R&R
- 26 October 2011
- Published by Wiley in Quality and Reliability Engineering International
- Vol. 28 (8) , 807-823
Random Effects Model for Attribute Gauge R&R
- Open Access
- 1 January 2011
- Published by Periodica Polytechnica Budapest University of Technology and Economics in Periodica Polytechnica Chemical Engineering
- Vol. 55 (1) , 17
Overdispersion at the Binomial and Multinomial Distribution
Overdispersion at the Binomial and Multinomial Distribution
- 1 January 2011
- Published by Periodica Polytechnica Budapest University of Technology and Economics in Periodica Polytechnica Chemical Engineering
- Vol. 55 (1) , 17
Open AccessOverdispersion at the Binomial and Multinomial Distribution
Overdispersion at the Binomial and Multinomial Distribution
- 1 January 2011
- Published by Inderscience Publishers in International Journal of Quality Engineering and Technology
- Vol. 2 (1) , 75
Critique of the AIAG cross-tabulation procedure for attribute gauge R&R study
The Automotive Industry Action Group's manual for attribute measurement system analysis has two major deficiencies: 1) the improper use of cross-tabulation and Cohen's kappa when operators are compared in case of repeated ratings, and; 2) calculation of the probabilities of wrong decisions with the Bayes theorem, however the conditions of its application are not fulfilled. Besides the AIAG manual we reviewed the approaches to attribute measurement system analysis proposed in the literature and used by some of the most popular statistical software. The conclusion is that all the methods referred to are statistically flawed. They do not properly consider the multiple ratings. The need has arisen for a different approach.
- 1 January 2011
- Published by Inderscience Publishers in International Journal of Quality Engineering and Technology
- Vol. 2 (1) , 75
Critique of the AIAG cross-tabulation procedure for attribute gauge R&R study
The Automotive Industry Action Group's manual for attribute measurement system analysis has two major deficiencies: 1) the improper use of cross-tabulation and Cohen's kappa when operators are compared in case of repeated ratings, and; 2) calculation of the probabilities of wrong decisions with the Bayes theorem, however the conditions of its application are not fulfilled. Besides the AIAG manual we reviewed the approaches to attribute measurement system analysis proposed in the literature and used by some of the most popular statistical software. The conclusion is that all the methods referred to are statistically flawed. They do not properly consider the multiple ratings. The need has arisen for a different approach.